newsfilter
← Latest News
GlobeNewswire·

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

  • TG Therapeutics announced that Chairman & CEO Michael S. Weiss will participate in the Goldman Sachs 47th Annual Healthcare Conference on June 8-10, 2026, at the Loews Miami Beach Hotel.
  • The scheduled fireside chat will occur on Tuesday, June 9, 2026, at 2:00 PM ET.
  • A live webcast of the event will be accessible via the Events page on the Company's investor relations website.
  • TG Therapeutics operates as a commercial-stage biotechnology company focused on B-cell disease treatments.
  • The FDA has approved BRIUMVI for adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, & active secondary progressive disease.
  • BRIUMVI has also received regulatory approvals outside the U.S. for treating adult patients with active multiple sclerosis defined by clinical or imaging features.